Literature DB >> 16912650

Polymorphonuclear leukocyte dysfunction syndrome in patients with increasing sepsis severity.

Ines Kaufmann1, Alwin Hoelzl, Florian Schliephake, Theresia Hummel, Alexander Chouker, Klaus Peter, Manfred Thiel.   

Abstract

Production of oxygen radicals is required for both microbicidal and tissue-toxic effector functions of granulocytes. Inasmuch as an ambivalent role of polymorphonuclear leukocytes (PMNs) may become apparent during sepsis, we studied levels of hydrogen peroxide (H2O2) production by PMNs depending upon the nature of different particulate and soluble stimuli in patients with increasing sepsis severity. Patients with sepsis (n = 15), severe sepsis (n = 12), or septic shock (n = 33) were prospectively enrolled in the study. Healthy volunteers of comparable age and sex served as controls (n = 50). Unopsonized and opsonized zymosan particles were used to assess adhesion, phagocytosis, and the associated H2O2 production. Zymosan particles are rich in beta-glucans and lectin structures that are known to trigger H2O2 production via two major non-toll-like receptor pathogen recognition receptors, comprising the lectin-binding site in the alpha-chain (CD11b) of the complement receptor type 3 and the more recently identified nonclassical C-type lectin, dectin-1. To determine H2O2 production upon cell activation by soluble stimuli, PMNs were activated by the chemotactic tripeptide (N-formyl-methionyl-leucyl-phenylalanine [fMLP]) alone or after priming of cells by preincubation with tumor necrosis factor alpha. To get insight into the changes of fMLP receptor classical intracellular signaling pathways, PMNs were also incubated with the calcium ionophore A23187 and the phorbol ester phorbol myristate acetate, bypassing receptor-dependent signal transduction to directly activate calcium/calmodulin kinase- and protein kinase C-dependent pathways, respectively. As compared with healthy volunteers, levels of H2O2 production by PMNs from septic patients varied depending upon the nature of the activating signal: reduced (zymosan), unchanged (phorbol myristate acetate, opsonized zymosan), and enhanced (spontaneous, fMLP, fMLP + tumor necrosis factor alpha, A23187), with the changes most pronounced in patients with septic shock. Specifically, phagocytosis of zymosan and the associated H2O2 production were significantly decreased whereas spontaneous and stimulated H2O2 production elicited by soluble stimuli strongly increased. Thus, these findings suggest the development of a PMN dysfunction syndrome in patients with increasing sepsis severity. Moreover, as binding of zymosan particles to the PMNs' surface remained unchanged despite increasingly suppressed phagocytosis and associated H2O2 production, observed effects are likely to reflect defects in signaling by the lectin-binding site of CD11b and/or the beta-glucan receptor dectin-1, respectively.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16912650     DOI: 10.1097/01.shk.0000223131.64512.7a

Source DB:  PubMed          Journal:  Shock        ISSN: 1073-2322            Impact factor:   3.454


  33 in total

1.  Toll-like receptor 1/2 stimulation induces elevated interleukin-8 secretion in polymorphonuclear leukocytes isolated from preterm and term newborn infants.

Authors:  Nathan L Thornton; Mark J Cody; Christian C Yost
Journal:  Neonatology       Date:  2011-09-23       Impact factor: 4.035

2.  Sepsis: redox mechanisms and therapeutic opportunities.

Authors:  Shyam Biswal; Daniel G Remick
Journal:  Antioxid Redox Signal       Date:  2007-11       Impact factor: 8.401

Review 3.  Sepsis pathophysiology and anesthetic consideration.

Authors:  Koichi Yuki; Naoka Murakami
Journal:  Cardiovasc Hematol Disord Drug Targets       Date:  2015

4.  Recombinant human milk fat globule-EGF factor 8 produces dose-dependent benefits in sepsis.

Authors:  Kavin G Shah; Rongqian Wu; Asha Jacob; Ernesto P Molmenti; Jeffrey Nicastro; Gene F Coppa; Ping Wang
Journal:  Intensive Care Med       Date:  2011-09-23       Impact factor: 17.440

5.  The augmented neutrophil respiratory burst in response to Escherichia coli is reduced in liver cirrhosis during infection.

Authors:  T Bruns; J Peter; S Hagel; A Herrmann; A Stallmach
Journal:  Clin Exp Immunol       Date:  2011-03-17       Impact factor: 4.330

6.  Phagocytosis by Fibrocytes as a Mechanism to Decrease Bacterial Burden and Increase Survival in Sepsis.

Authors:  Dalis Collins; Christopher Fry; Bethany B Moore; Jean A Nemzek
Journal:  Shock       Date:  2019-04       Impact factor: 3.454

7.  Preclinical evaluation of targeting the Nrf2 pathway by triterpenoids (CDDO-Im and CDDO-Me) for protection from LPS-induced inflammatory response and reactive oxygen species in human peripheral blood mononuclear cells and neutrophils.

Authors:  Rajesh K Thimmulappa; Ralph J Fuchs; Deepti Malhotra; Catherine Scollick; Kassim Traore; Jay H Bream; Michael A Trush; Karen T Liby; Michael B Sporn; Thomas W Kensler; Shyam Biswal
Journal:  Antioxid Redox Signal       Date:  2007-11       Impact factor: 8.401

8.  Neutrophil azurophilic granule exocytosis is primed by TNF-α and partially regulated by NADPH oxidase.

Authors:  Renee M Potera; Melissa J Jensen; Brieanna M Hilkin; Gina K South; Jessica S Hook; Emily A Gross; Jessica G Moreland
Journal:  Innate Immun       Date:  2016-09-23       Impact factor: 2.680

9.  Immature dendritic cell-derived exosomes rescue septic animals via milk fat globule epidermal growth factor-factor VIII [corrected].

Authors:  Michael Miksa; Rongqian Wu; Weifeng Dong; Hidefumi Komura; Dhruv Amin; Youxin Ji; Zhimin Wang; Haichao Wang; Thanjavur S Ravikumar; Kevin J Tracey; Ping Wang
Journal:  J Immunol       Date:  2009-10-07       Impact factor: 5.422

10.  Type I interferon signaling in hematopoietic cells is required for survival in mouse polymicrobial sepsis by regulating CXCL10.

Authors:  Kindra M Kelly-Scumpia; Philip O Scumpia; Matthew J Delano; Jason S Weinstein; Alex G Cuenca; James L Wynn; Lyle L Moldawer
Journal:  J Exp Med       Date:  2010-01-13       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.